Woodline Partners’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Woodline Partners's FDMT Position: Q3 2026 in Review
Woodline Partners held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 200,001 shares worth $2.86M. The position accounts for 0.01% of the portfolio, ranked #823.
Woodline Partners first reported a position in FDMT in Q4 2020 and has held it in 9 quarters since. The position peaked at $4.29M in Q4 2020. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Woodline Partners held 200,001 shares of 4D Molecular Therapeutics worth $2.86M as of Q3 2026.
- Woodline Partners left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
- 4D Molecular Therapeutics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #823 holding.
- Woodline Partners first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 9 quarters since.
- Woodline Partners's 4D Molecular Therapeutics position peaked at $4.29M in Q4 2020.
- 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.